Compounded semaglutide is not the same drug as Ozempic. It contains the same active ingredient, but the manufacturing, purity testing, and regulatory oversight are different. The FDA inspected 38 compounding pharmacies in late 2025 and found potency ranging from 62% to 143% of labeled dose.
That means one vial might deliver barely half the intended dose while another delivers nearly 50% more. For a drug that causes dose-dependent nausea, vomiting, and (rarely) pancreatitis, that variance matters.
The real-world signal: poison control calls involving semaglutide rose from roughly 1,500 per year to over 8,000 per year, according to a Journal of Medical Toxicology study from UTSA/South Texas Poison Center (published February 2026, covering 2012-2023 data). Semaglutide accounted for 64% of all GLP-1-related poison center contacts. The hospital referral rate climbed from 23% to 33.5% over the study period.
TL;DR
- Compounded semaglutide uses the same molecule but is not FDA-approved or bioequivalent-tested
- FDA inspections of 38 pharmacies found potency between 62-143% of label
- 21 compounding pharmacies received warning letters in March 2026
- Compounders legally produced semaglutide during the shortage (ended February 2025)
- After the shortage ended, compounding became illegal without individual patient prescriptions under 503A
- Patients on compounded GLP-1s should transition to FDA-approved versions
How we researched this
We pulled FDA warning letters, enforcement actions, and inspection reports from the openFDA enforcement endpoint and FDA.gov. Potency data comes from FDA laboratory analyses published in the March 2026 warning letters. Timeline data cross-referenced with our GLP-1 recall tracker.
What "compounded" actually means
A compounding pharmacy mixes drugs to order, typically for patients with specific needs (allergies to inactive ingredients, pediatric dosing, discontinued formulations). Two regulatory categories exist:
| Type | Oversight | Scale | When legal for GLP-1s |
|---|---|---|---|
| 503A (traditional) | State pharmacy board | Individual prescriptions | During shortage only |
| 503B (outsourcing facility) | FDA-registered, inspected | Bulk without patient-specific Rx | During shortage only |
The legal basis for compounding GLP-1 drugs was Section 503A of the FD&C Act, which allows compounders to produce copies of commercially available drugs when those drugs are on the FDA Drug Shortage List.
Semaglutide was on the shortage list from 2022 until February 21, 2025. During that window, compounders had a legal argument for production. After that date, they did not.
The potency problem
The FDA's lab results from inspected pharmacies tell the story. Compounded semaglutide samples showed:
- Low-end outliers: 62% of labeled potency (patient gets a sub-therapeutic dose)
- High-end outliers: 143% of labeled potency (patient gets a 43% overdose)
- Mean variance: roughly 20% off label in either direction
- Sterility failures: 6 of 38 pharmacies failed USP sterility testing
For context, FDA-approved Ozempic must test between 90-110% of labeled potency. Every pen, every lot. Manufacturing deviations trigger recalls. Novo Nordisk's production facilities undergo FDA inspection before and after approval.
Compounded versions face no pre-market potency requirement. A 503A pharmacy may test its product, but the FDA does not review or approve those tests before the drug ships.
Why potency variance matters for semaglutide
Semaglutide is dose-titrated for a reason. Patients start at 0.25 mg weekly, increase to 0.5 mg after four weeks, then to 1.0 mg, with some reaching 2.4 mg for weight loss. Each step lets the body adjust. The nausea, vomiting, and GI side effects that drive about 10% of patients to discontinue are dose-related.
The FDA issued an alert in July 2024 specifically about compounded semaglutide dosing errors, noting that vial/syringe/unit confusion caused patients to inject 5 to 20 times the intended dose. Unlike Ozempic's pre-filled pen (which delivers a fixed dose per click), compounded vials require manual syringe measurement. A decimal point error or unit confusion turns a 0.25 mg dose into 2.5 mg or 5.0 mg.
A patient prescribed 1.0 mg who receives 1.43 mg (143% potency) is getting a dose they were never titrated to. A patient receiving 0.62 mg (62% potency) may see no efficacy and assume the drug does not work for them.
Sterility: the bigger risk
Potency variance causes discomfort and poor outcomes. Sterility failures can cause serious harm.
Injectable drugs must be sterile. Period. Contaminated injectables have caused deaths in the US — the 2012 New England Compounding Center meningitis outbreak killed 76 people from contaminated methylprednisolone injections.
The FDA found sterility failures in 6 of 38 inspected GLP-1 compounders (16%). Issues included:
- Inadequate clean room environments
- Lack of end-product sterility testing
- No environmental monitoring programs
- Beyond-use dating assigned without stability data
None of the 38 inspected pharmacies had reported contamination-related patient harm. But the absence of testing means contamination could exist undetected.
Compounded vs. brand: what you actually get
| Factor | Brand Ozempic/Wegovy | Compounded semaglutide |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide (same molecule) |
| FDA-approved | Yes | No |
| Potency testing | 90-110% required, every lot | Varies by pharmacy |
| Sterility assurance | Full cGMP manufacturing | Depends on pharmacy's practices |
| Delivery device | Pre-filled pen (precise dosing) | Typically vial + syringe (manual) |
| Cost (no insurance) | $900-1,300/month | $150-400/month |
| Insurance coverage | Often covered (varies by plan) | Rarely covered |
| Legal status (post-Feb 2025) | Fully legal | Legal only under narrow 503A conditions |
The cost difference drove the compounding market. At $900+/month without insurance, brand Ozempic is unaffordable for many patients. Compounders charged $150-300/month. The economics were compelling, even if the risk profile was different.
The legal situation after February 2025
The FDA removed semaglutide from its Drug Shortage List on February 21, 2025. After that date:
503A pharmacies can still compound semaglutide for individual patients if a licensed prescriber determines the patient needs a specific modification (different concentration, allergy to an inactive ingredient). But "cheaper" is not a qualifying reason. Simply reproducing the commercial product at a lower price is not legal compounding.
503B outsourcing facilities lost their basis entirely. Without a shortage, they cannot produce copies of commercially available drugs in bulk.
Enforcement reality: The FDA issued 21 warning letters in March 2026. Criminal referrals have been reported for the most egregious violators. But hundreds of smaller 503A pharmacies still advertise "semaglutide injections" — enforcement takes time, and state boards vary in their aggressiveness.
What patients on compounded semaglutide should do
If you are taking compounded semaglutide or tirzepatide:
- Talk to your prescriber about transitioning to FDA-approved versions
- Check insurance coverage — many plans now cover Wegovy for weight loss (not all, see our GLP-1 insurance coverage guide)
- Novo Nordisk patient assistance programs exist for uninsured patients
- Do not stop abruptly — rebound weight gain is common; plan the transition with your provider
- Report side effects to the FDA's MedWatch system if you experienced unusual reactions
The counterfeit problem (separate from compounding)
Counterfeit Ozempic pens are a different issue from compounded semaglutide. Counterfeits are fake brand products sold as genuine, often through unauthorized distributors or online pharmacies.
The FDA seized counterfeit Ozempic pens in April 2025 (lot PAR0362) and again in December 2025. Lab analysis of seized counterfeits found some contained insulin instead of semaglutide — a potentially life-threatening substitution for non-diabetic patients.
If your Ozempic pen came from a non-US pharmacy, an online marketplace, or an unusually cheap source, verify the lot number at Novo Nordisk's verification site or call their patient line.
FAQ
Is compounded semaglutide the same as Ozempic? Same active molecule, different everything else. No FDA approval, no bioequivalence testing, no standardized manufacturing controls. The FDA has stated that compounded semaglutide sodium and semaglutide acetate (the salt forms most compounders use) "have not been shown to be safe and effective." The potency, sterility, and inactive ingredients all depend on the individual pharmacy's practices.
Can I still get compounded semaglutide legally? Under narrow conditions. A 503A pharmacy can compound it for you with a valid prescription if your prescriber documents a clinical reason beyond cost (allergy to an excipient, need for a non-standard concentration). Bulk production by 503B facilities is no longer legal for semaglutide.
Has anyone died from compounded semaglutide? No deaths have been publicly attributed to compounded semaglutide as of August 2026. Hospitalizations from dosing errors and allergic reactions to non-standard excipients have been reported to FAERS, but comprehensive adverse event data for compounded products is limited because reporting is voluntary.
Why is brand Ozempic so expensive? Patent protection, no generic competition (first semaglutide generics expected 2026-2027), high manufacturing complexity for peptide drugs, and Novo Nordisk's pricing strategy. The Inflation Reduction Act's Medicare negotiation selected semaglutide for 2027 price negotiations.
What about compounded tirzepatide (Mounjaro/Zepbound)? Same situation. Tirzepatide left the shortage list in December 2024 (with a grace period through February 2025). The FDA's enforcement applies equally to tirzepatide compounders.
How do I know if my pharmacy is legitimate? Check your state board of pharmacy's license verification. For 503B outsourcing facilities, check the FDA's registered outsourcing facility list at FDA.gov. A legitimate compounder should provide certificates of analysis (potency testing) for each batch.
Will generic semaglutide be available soon? Novo Nordisk's key semaglutide patents expire in 2026-2031 (various formulations and methods). The first generic/biosimilar applications are expected in 2026-2027. Actual market availability of cheaper FDA-approved alternatives is likely 2027-2028.
Where can I report problems with compounded GLP-1 drugs? FDA MedWatch (online or by phone at 1-800-FDA-1088). Also report to your state board of pharmacy and your prescriber.
Sources: FDA warning letters (March 7, 2026), FDA Drug Shortage Database, openFDA enforcement endpoint, FDA laboratory analysis reports cited in warning letters, FDA safety alert on compounded semaglutide dosing errors (July 2024), Journal of Medical Toxicology poison control study (UTSA/South Texas Poison Center, February 2026, DOI 10.1007/s13181-026-01121-z). Last verified August 2026.
Want to track GLP-1 recalls and enforcement actions programmatically? The MyfitByte API monitors FDA enforcement data for drug safety signals.
Related reading
- GLP-1 and Ozempic Recalls 2026: What the FDA Data Shows — the full recall timeline and enforcement actions
- Does Insurance Cover Wegovy & Zepbound in 2026? — coverage options if you're transitioning from compounded
- How Many Americans Take GLP-1 Drugs? — 15 million users and counting
- Ozempic Side Effects: What 69,000 FDA Reports Show — adverse event data from FAERS
- Medicare Drug Spending 2024 — GLP-1s hit $20B in Medicare spending alone
Published on 2026-08-25 · 9 min read
← Back to all articles